Oncotype DX assay for predicting recurrence of stage II colon cancer

In this era of personalized medicine, it becomes ever more critical to utilize all available tools in making treatment decisions for cancer patients. Now, a multigene assay offers a validated clinical tool for improving risk assessment and treatment decisions following surgery for stage II colon cancer. Choosing adjuvant therapy for this disease poses a particularly difficult treatment conundrum.

FROM THE ONCOLOGIST'S PERSPECTIVE
Why we need a new prognostic test for colon cancer

Lee S. Schwartzberg, MD, FACP,
The West Clinic, Memphis, TN

FROM THE PATHOLOGIST'S PERSPECTIVE
New multigene assay offers valuable insight into predicting tumor behavior

Robert C. Babkowski, MD,
Stamford Hospital, Stamford, CT

http://www.communityoncology.net/journal/articles/0705198.pdf